Navidea Biopharma (NAVB) Tops Q3 EPS by 2c; Revenue Beats

November 3, 2016 8:45 AM EDT
Get Alerts NAVB Hot Sheet
Trade NAVB Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Navidea Biopharma (NYSE: NAVB) reported Q3 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $8.5 million versus the consensus estimate of $6.47 million.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment